Nurix Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Mailing Address 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Phone (415) 660-5320
Fiscal Year End 1130
EIN 270838048
Financial Overview
FY2025
-$143.95M
Net Income
$688.13M
Total Assets
$149.39M
Total Liabilities
$538.75M
Stockholders' Equity
$246.96M
Cash & Equivalents
$-2.65
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 10-K Annual financial report | January 28, 2026 | View on SEC |
Annual Reports
10-K January 28, 2026
- Advanced pipeline with three key drug candidates (Bexobrutide, Zelebrudomide, NX-1607) progressing through clinical trials.
- Strategic collaborations with major pharmaceutical companies including Gilead Sciences, Sanofi, and Pfizer.
Insider Trading
STRONG SELL 3 insiders
11 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.